

## References

L-221

1. UPMC University of Pittsburgh Medical Center. ThyroSeq® - Thyroid Cancer Next-Generation Sequencing Panel. Interpace Diagnostics. The ThyGenX® and ThyraMIR™ Molecular Diagnostic Report.
2. NCCN. National Comprehensive Cancer Network. Thyroid Carcinoma (Version 2.2017).
3. Beaudenon-Huibregtse S, Alexander EK, Guttler RB, et al. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules. *Thyroid*. Oct 2014;24(10):1479-1487.
4. Giordano TJ, Beaudenon-Huibregtse S, Shinde R, et al. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens. *Human Pathology*. Jul 2014;45(7):1339-1347.
5. Labourier E, Shifrin A, Busseniers AE, et al. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology. *J Clin Endocrinol Metab*. Jul 2015;100(7):2743-2750.
6. Wylie D, Beaudenon-Huibregtse S, Haynes BC, Giordano TJ, Labourier E. Molecular classification of thyroid lesions by combined testing for miRNA gene expression and somatic gene alterations. *The Journal of Pathology. Clinical Research*. Apr 2016;2(2):93-103.